Ruth Swann
YOU?
Author Swipe
View article: Geographic inequalities in diagnostic testing delays in England before and after COVID
Geographic inequalities in diagnostic testing delays in England before and after COVID Open
Diagnostic testing delays worsened during the COVID-19 pandemic, but it is unclear whether geographic inequalities have deepened. Using publicly-available data in England for nine tests, we compared waiting times across 106 local areas in …
View article: Chemotherapy use in ovarian cancer patients diagnosed 2012–2017 in Australia, Canada, Norway and the UK: An International Cancer Benchmarking Partnership (ICBP) population-based study
Chemotherapy use in ovarian cancer patients diagnosed 2012–2017 in Australia, Canada, Norway and the UK: An International Cancer Benchmarking Partnership (ICBP) population-based study Open
Even within the same age groups and stage strata, use of chemotherapy varied substantially between jurisdictions during the mid-2010s. Future work should examine use of surgery in combination with chemotherapy. The reasons for the internat…
View article: Chemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012–2017: an ICBP population-based study
Chemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012–2017: an ICBP population-based study Open
Background International variation in lung cancer survival may be partly explained by variation in stage-specific treatment use, but relevant comparative evidence is sparse. As part of the International Cancer Benchmarking Partnership, we …
View article: Variation in the use of primary care-led investigations prior to a cancer diagnosis: analysis of the National Cancer Diagnosis Audit
Variation in the use of primary care-led investigations prior to a cancer diagnosis: analysis of the National Cancer Diagnosis Audit Open
Introduction Use of investigations can help support the diagnostic process of patients with cancer in primary care, but the size of variation between patient group and between practices is unclear. Methods We analysed data on 53 252 patien…
View article: Factors affecting prostate cancer detection through asymptomatic prostate-specific antigen testing in primary care in England: evidence from the 2018 National Cancer Diagnosis Audit
Factors affecting prostate cancer detection through asymptomatic prostate-specific antigen testing in primary care in England: evidence from the 2018 National Cancer Diagnosis Audit Open
Background Prostate-specific antigen (PSA) is used in primary care for prostate cancer detection, either for symptomatic assessment or asymptomatic testing following an informed decision. Aim To estimate the proportion of patients with pro…
View article: Predictors and consequences of different pathways to emergency diagnosis of cancer in England: Evidence from linked national audit and cancer registration data
Predictors and consequences of different pathways to emergency diagnosis of cancer in England: Evidence from linked national audit and cancer registration data Open
We profile different pathways to emergency diagnosis and identify opportunities to improve diagnostic processes for these patients.
View article: Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study
Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study Open
International Cancer Benchmarking Partnership (funded by the Canadian Partnership Against Cancer, Cancer Council Victoria, Cancer Institute New South Wales, Cancer Research UK, Danish Cancer Society, National Cancer Registry Ireland, The C…
View article: Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study Open
International Cancer Benchmarking Partnership (funded by the Canadian Partnership Against Cancer, Cancer Council Victoria, Cancer Institute New South Wales, Cancer Research UK, Danish Cancer Society, National Cancer Registry Ireland, The C…
View article: The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit
The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit Open
View article: Pre-Referral Primary Care Blood Tests and Symptom Presentation before Cancer Diagnosis: National Cancer Diagnosis Audit Data
Pre-Referral Primary Care Blood Tests and Symptom Presentation before Cancer Diagnosis: National Cancer Diagnosis Audit Data Open
Background: Blood tests can support the diagnostic process in primary care. Understanding how symptomatic presentations are associated with blood test use in patients subsequently diagnosed with cancer can help to benchmark current practic…
View article: Supplementary Table 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Table 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 52K, Clinicopathology data for whole human diagnostic cancer specimens.
View article: Supplementary Figure 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 2029K, Examples of tumour types classified as predominantly tumour vessel or stromal vessel phenotypes from TMA cores.
View article: Supplementary Figure 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 211K, Additional biomarker responses to DC101 in Calu-3 xenograft model.
View article: Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers Open
Purpose: Vascular endothelial growth factor (VEGF) signaling is key to tumor angiogenesis and is an important target in the development of anticancer drugs. However, VEGF receptor (VEGFR) expression in human cancers, particularly th…
View article: Supplementary Figure Legend from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure Legend from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 22K
View article: Supplementary Table 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Table 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 52K, Clinicopathology data for human cancer specimens employed in tissue microarray analyses.
View article: Supplementary Table 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Table 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 90K, TaqMan Fluidigm probe sets.
View article: Supplementary Figure 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 121K, Intra-sample distribution of the two phenotypes within diagnostic samples and concordance with the phenotype classifications for matched TMA cores.
View article: Supplementary Figure 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 260K, H+E comparison of typical morphologies of pancreatic neuroendocrine cancer and pancreatic adenocarcinoma and additional biomarker analyses of the two phenotypes.
View article: Supplementary Figure 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 211K, Additional biomarker responses to DC101 in Calu-3 xenograft model.
View article: Supplementary Table 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Table 4 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 90K, TaqMan Fluidigm probe sets.
View article: Supplementary Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
Supplementary Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers Open
Supplementary Tables S1-S2.
View article: Supplementary Table 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Table 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 52K, Clinicopathology data for whole human diagnostic cancer specimens.
View article: Supplementary Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
Supplementary Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers Open
Supplementary Tables S1-S2.
View article: Supplementary Figure 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 2029K, Examples of tumour types classified as predominantly tumour vessel or stromal vessel phenotypes from TMA cores.
View article: Supplementary Table 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Table 1 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 14K, Cancer indications approved for VEGF signalling inhibitors.
View article: Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
Data from Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers Open
Purpose: Vascular endothelial growth factor (VEGF) signaling is key to tumor angiogenesis and is an important target in the development of anticancer drugs. However, VEGF receptor (VEGFR) expression in human cancers, particularly th…
View article: Data from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Data from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
Purpose: The aim of the study was to investigate the vascular and stromal architecture of preclinical tumor models and patient tumor specimens from malignancies with known clinical outcomes to VEGFi treatment, to gain insight into p…
View article: Supplementary Table 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Table 2 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 52K, Clinicopathology data for human cancer specimens employed in tissue microarray analyses.
View article: Supplementary Figure 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Supplementary Figure 3 from Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Open
PDF file - 260K, H+E comparison of typical morphologies of pancreatic neuroendocrine cancer and pancreatic adenocarcinoma and additional biomarker analyses of the two phenotypes.